Biocryst Pharmaceuticals Inc SEC Filings

BioCryst Pharmaceuticals (BCRX) Form 144 notifies a proposed sale of 70,000 common shares through Fidelity Brokerage Services with an aggregate market value of $595,870.74. The shares are scheduled for sale on 08/13/2025 on NASDAQ and come from a reported total outstanding share count of 209,920,430.

The filing shows the shares derive from stock options: 30,000 from an option granted 05/29/2019 and 40,000 from an option granted 05/12/2020, with the consideration listed as cash. The filer reports Nothing to Report for sales in the past three months and includes the standard representation that no undisclosed material adverse information is known to the seller.

BioCryst Pharmaceuticals, Inc. has registered 11,000,000 shares of common stock for issuance under its Stock Incentive Plan, which was amended and restated on April 21, 2025 and approved by stockholders on June 12, 2025. The Registration Statement incorporates by reference the companys Annual Report for the year ended December 31, 2024 and Quarterly Reports filed for the quarters ended March 31, 2025 and June 30, 2025, as well as a series of Current Reports filed between February and August 2025.

The filing describes the companys indemnification framework under Delaware law, noting statutory protections under Section 145 and Section 102(b)(7), the Certificate of Incorporation and Bylaws indemnification provisions, and existing directors and officers liability insurance. The filing also states that indemnification for Securities Act liabilities may be deemed unenforceable under SEC precedent. Exhibits include counsels opinion, auditor consent, the amended Stock Incentive Plan (incorporated by reference), a power of attorney, and the fee table.

BioCryst Pharmaceuticals announced that Dr. Helen Thackray will resign as Chief Research and Development Officer effective September 1, 2025. She said she will pursue new opportunities and cited no disagreement with the Board. The Company and Dr. Thackray entered a Separation Agreement providing one year of continued base salary, payment of her 2025 annual incentive plan bonus based on actual performance plus payment of her target 2025 bonus, up to 12 months of company-paid group health continuation, up to six months of outplacement services, and accelerated vesting of equity awards scheduled to vest in 2026. The Compensation Committee also approved a Consulting Agreement through December 31, 2025 under which she will provide transition services for a $12,500 monthly fee, with continued vesting of equity awards during the consulting period and six-month post-consulting option exercisability. These arrangements are intended to support an orderly transition while creating near-term compensation and equity vesting obligations.

BioCryst Pharmaceuticals, Inc. (BCRX) — 10-Q for quarter ended June 30, 2025. Key operational and financial metrics from the filing:

• Revenues: $163,353 thousand (Q2 2025) vs $109,332 thousand (Q2 2024); six months $308,887 thousand vs $202,093 thousand.
• Profitability: Net income $5,085 thousand for Q2 2025 vs a net loss in Q2 2024; six months net income $5,117 thousand vs loss $48,053 thousand.
• Liquidity & balance sheet: Cash and cash equivalents $88,033 thousand; short-term investments $172,005 thousand; total assets $457,188 thousand; stockholders' deficit $(421,594) thousand (improved vs Dec 31, 2024).
• Financing & obligations: Secured term loan $242,794 thousand; royalty financing obligations non-current $447,842 thousand; Pharmakon term loan principal repaid $69,508 thousand year-to-date.
• Other material item: On June 27, 2025 the company entered a definitive agreement to sell BioCryst Ireland (European ORLADEYO business) and has classified assets and liabilities held for sale.

Management states available resources at June 30, 2025 are sufficient to fund operations for at least the next 12 months.

BioCryst Pharmaceuticals (Nasdaq: BCRX) filed an 8-K announcing a planned CEO transition. Incumbent President & CEO Jon Stonehouse will retire on 31 Dec 2025 after 17 years at the helm; he reports no disagreements and will stay on the board. He retains eligibility for his 2025 bonus and up to 18 months of subsidised health coverage.

The board named current Chief Commercial Officer Charlie Gayer (age 54) as President effective 1 Aug 2025 and as CEO effective 1 Jan 2026. Compensation terms include:

• 2025 base salary raised to $675k; annual incentive target blended at 70-75% of salary.
• From 2026: base salary $775k; AIP target set at 85% of salary.
• Severance (without cause / post-change-of-control): two years of salary, 2× target bonus over two years, and up to 12 months of subsidised health coverage.

The board will expand from nine to ten directors and elect Gayer to the new seat beginning 1 Jan 2026 (term ends 2028). No related-party transactions or disagreements were disclosed, and Gayer will initially serve on no board committees.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) filed an 8-K announcing a key leadership change. Effective 7 July 2025, the Board appointed Babar Ghias (46) as Chief Financial Officer, Principal Accounting Officer and Head of Corporate Development. Mr. Ghias brings two decades of healthcare and life-sciences experience, including CFO roles at AvenCell Therapeutics and Marathon Pharmaceuticals and M&A advisory work at Credit Suisse.

Compensation package includes: (i) base salary of $560,000; (ii) annual incentive target equal to 70 % of salary (full-year eligible for 2025); (iii) a $160,000 one-time cash bonus payable within 30 days; and (iv) Inducement Grants on 31 July 2025 of 147,000 RSUs and 305,000 stock options, vesting in four equal annual tranches from the first anniversary of grant.

The filing states Mr. Ghias has no related-party transactions, no special arrangements leading to his appointment, and no family relationships with existing directors or officers. A press release (Ex. 99.1) concurrently discloses the hire.

Investor take-away: While the event does not change current financial guidance, BioCryst strengthens its executive bench with a CFO possessing commercialisation and deal-making expertise that could support future capital strategy and business development.